TL/DR –
Laura is joining Philips to help improve people’s health and well-being through innovation, combining science, technology, and data. Following her departure, Philipp Harbach will serve as the interim Chief Science and Technology Officer at Merck KGaA, a global company in healthcare, life sciences, and electronics. Philips has partnerships with WellSpan Health for a strategic alliance and Edwards Lifesciences, with whom they developed an AI-powered solution for real-time guidance during minimally invasive mitral valve repair.
Philips looks forward to improving healthcare through innovation
Philips is committed to enhancing people’s health and well-being by harnessing the potentials of innovative technologies, as mentioned on LinkedIn.
The company is eager to collaborate with new associates, clients, and partners to integrate science, technology, data, and digital skills to offer valuable solutions for patients, healthcare professionals, and consumers.
After the departure of Laura, Philipp Harbach steps in as the Interim Chief Science and Technology Officer at Merck KGaA.
Merck KGaA is an international science and technology organization that operates in healthcare, life sciences, and electronics. Its healthcare division invents novel medicines and technologies in the fields of oncology, immunology, neurology, and fertility. Meanwhile, its Life Science branch provides tools and solutions that aid pharmaceutical research, bioprocessing, and global healthcare innovation.
Key Phillips Partnerships
WellSpan Health
Under the leadership of CEO Roxanna Gapstur and headquartered in York, Pennsylvania, WellSpan Health joined forces with Philips in June 2026 for a seven-year strategic alliance. This partnership involves advanced imaging, diagnostics, AI, and research. The goal is to co-develop and validate new technologies within WellSpan’s 12 hospitals and extended network to enhance clinical workflows, efficiency, and patient care.
Edwards Lifesciences
With Bernard Zovighian as CEO and based in Irvine, California, Edwards Lifesciences partnered with Philips to create DeviceGuide. This AI-powered solution offers real-time guidance during minimally invasive mitral valve repair. The technology merges Philips’ imaging expertise with Edwards’ structural heart technology to monitor and display the PASCAL Ace repair device. The FDA approved this device in March 2026.
—
Read More Health & Wellness News ; US News